Company:  PROTALIX BIOTHERAPEUTICS, ... (PLX)
Form Type:  10-K
Filing Date:  2/27/2012 
CIK:  0001006281 
Address:  2 SNUNIT ST
SCIENCE PARK, POB 455
 
City, State, Zip:  CARMIEL,  20100 
Telephone:  972-4-988-9488 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.13  
Change: 
-0.04 (-0.96%)  
Trade Time: 
04:01 PM EST  
Market Cap: 
$386.49M
Description of Business
We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx� protein expression system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary, biobetter and biosimilar versions of recombinant therapeutic proteins, based on our plant cell-based expression technology, that primarily target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe ProCellEx will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant proteins currently marketed for the same indications.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I
      Item 1. Business
      Item 1A. Risk Factors
      Item 1B. Unresolved Staff Comments
      Item 2. Properties
      Item 3. Legal Proceedings
      Item 4. Mine Safety Disclosures
    PART II
      Item 5. Market for Registrant's Common Equity, Related ...
      Item 6. Selected Financial Data
      Item 7. Management's Discussion and Analysis of ...
        Liquidity and Capital Resources
      Item 7A. Quantitative and Qualitative Disclosures About ...
      Item 8. Financial Statements and Supplementary Data
      Item 9. Changes in and Disagreements with Accountants on ...
      Item 9A. Controls and Procedures
      Item 9B. Other Information
    PART III
      Item 10. Directors, Executive Officers and Corporate ...
        NAME AND TITLE
      Item 11. Executive Compensation
        COMPENSATION TABLE
        OPTIONS AGGREGATE
      Item 12. Security Ownership of Certain Beneficial Owners and ...
        BENEFICIAL OWNERS
      Item 13. Certain Relationships and Related Transactions, and ...
      Item 14. Principal Accountant Fees and Services
    PART IV
      Item 15. Exhibits and Financial Statement Schedules
    SIGNATURES
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    BALANCE SHEET
    INCOME STATEMENT
    STOCKHOLDERS EQUITY
    CASH FLOW
    CASH FLOW
    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      NOTE 11 - SUBSEQUENT EVENTS
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION
  EXHIBIT 32.2
    CERTIFICATION
BROKERAGE PARTNERS